CorMedix’s (CRMD) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of CorMedix (NASDAQ:CRMD) in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a $14.00 target price on the stock.

A number of other brokerages have also recently commented on CRMD. Weiss Ratings reiterated a “hold (c)” rating on shares of CorMedix in a report on Wednesday, October 8th. Needham & Company LLC lowered their price target on CorMedix from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th. Royal Bank Of Canada reiterated an “outperform” rating and set a $22.00 price objective (up previously from $21.00) on shares of CorMedix in a research report on Tuesday, October 21st. D Boral Capital raised shares of CorMedix from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Finally, Zacks Research raised shares of CorMedix from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 4th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, CorMedix presently has an average rating of “Buy” and an average price target of $17.86.

CorMedix Price Performance

CRMD stock opened at $7.63 on Thursday. CorMedix has a 52 week low of $5.60 and a 52 week high of $17.43. The firm has a market capitalization of $601.16 million, a P/E ratio of 3.70 and a beta of 1.36. The company has a fifty day simple moving average of $10.96 and a two-hundred day simple moving average of $11.59. The company has a quick ratio of 1.73, a current ratio of 1.94 and a debt-to-equity ratio of 0.39.

CorMedix (NASDAQ:CRMD) last announced its earnings results on Wednesday, November 12th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.78. The firm had revenue of $104.28 million for the quarter, compared to analysts’ expectations of $65.63 million. CorMedix had a net margin of 75.83% and a return on equity of 51.77%. The business’s revenue was up 810.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.05) EPS. Analysts anticipate that CorMedix will post -0.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Joseph Todisco sold 30,000 shares of CorMedix stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $12.00, for a total transaction of $360,000.00. Following the completion of the sale, the chief executive officer directly owned 509,496 shares in the company, valued at approximately $6,113,952. This trade represents a 5.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven W. Lefkowitz sold 40,000 shares of the company’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $11.88, for a total transaction of $475,200.00. Following the completion of the transaction, the director owned 80,498 shares in the company, valued at approximately $956,316.24. The trade was a 33.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 90,000 shares of company stock worth $1,095,200. 3.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CorMedix

A number of institutional investors have recently modified their holdings of CRMD. Comerica Bank raised its stake in shares of CorMedix by 454.6% during the third quarter. Comerica Bank now owns 2,690 shares of the company’s stock valued at $31,000 after acquiring an additional 2,205 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in CorMedix in the second quarter worth approximately $42,000. Caitong International Asset Management Co. Ltd increased its holdings in CorMedix by 666.6% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company’s stock worth $51,000 after purchasing an additional 3,813 shares during the period. State of Alaska Department of Revenue bought a new stake in CorMedix during the 3rd quarter valued at $54,000. Finally, USA Financial Formulas bought a new stake in CorMedix during the 2nd quarter valued at $55,000. 34.18% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Analyst support remains: D. Boral Capital reaffirmed a “buy” rating with a $14 target, and Needham maintained a buy rating despite trimming its target from $16 to $15 — these endorsements help provide demand support for the shares. Analyst notes
• Positive Sentiment: Management continuity: CEO Joseph Todisco signed an extended employment contract and will add the Chairman role while the prior chair moves to Lead Independent Director — the move signals board-level continuity during the reset. Leadership update
• Neutral Sentiment: Investor outreach / visibility: Management will present a corporate overview at the J.P. Morgan Healthcare Conference (Jan 12), which could provide additional color and catalyze trading flows depending on guidance detail and Q&A. JPM presentation
• Neutral Sentiment: Valuation / bullish commentary: Coverage pieces (Zacks, Yahoo analysis) argue the stock may be undervalued or worth reassessing after the recent operational reset; these are watch items but not immediate catalysts. Zacks coverage
• Negative Sentiment: Material FY-2026 guidance reset: Management trimmed FY-2026 revenue guidance to $300–$320M versus consensus (~$445M), creating a large miss expectation and driving heavy selling pressure. Guidance cut article
• Negative Sentiment: Preliminary results and reduced outlook triggered downside: Q4/FY-2025 preliminary numbers were reported but the updated FY-2026 revenue range and related messaging prompted immediate negative investor reaction and headlines about a stock crash. Preliminary results
• Negative Sentiment: Reimbursement risk flagged: Analysis notes emerging CMS reimbursement headwinds that could pressure future revenue realization and margins — this is a structural risk that could sustain downward pressure if unresolved. CMS reimbursement analysis

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.